Literature DB >> 14566466

[IgA nephropathy: frequent, but rarely diagnosed].

J Floege1, H-J Gröne.   

Abstract

IgA nephropathy (IgAN) is the most common type of glomerulonephritis in the western world. In the majority of cases, it manifests in adolescence or early adulthood as recurrent macrohematuria, frequently triggered by infections, or persistent microhematuria as well as mild proteinuria, hypertension and/or renal insufficiency. In view of the later, it is not surprising that IgAN is often a chance finding. The majority of affected persons probably never come to medical attention, since in autopsies a prevalence of up to 1% of the population has been reported. About 20-30% of patients with a diagnosis of IgAN suffer from chronic, slowly progressive renal failure. Predictors include the degree of proteinuria and arterial hypertension as well as the established renal impairment at the time of diagnosis. Early identification of this risk group is of particular importance, since adequate therapy can stop or at least retard the progression of renal failure. When end stage renal failure has developed and a renal transplant is performed, about 25% of the patients will experience a clinically relevant recurrence of IgAN with progressive graft dysfunction.

Entities:  

Mesh:

Year:  2003        PMID: 14566466     DOI: 10.1007/s00108-003-1026-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  42 in total

Review 1.  IgA nephropathy: recent developments.

Authors:  Jürgen Floege; John Feehally
Journal:  J Am Soc Nephrol       Date:  2000-12       Impact factor: 10.121

2.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.

Authors:  O Hotta; M Miyazaki; T Furuta; S Tomioka; S Chiba; I Horigome; K Abe; Y Taguma
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

3.  Steroid and cyclophosphamide in IgA nephropathy.

Authors:  D Roccatello; M Ferro; G Cesano; D Rossi; S Berutti; M Salomone; G Piccoli; L M Sena
Journal:  Nephrol Dial Transplant       Date:  2000-06       Impact factor: 5.992

4.  Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.

Authors:  Y Kanno; H Okada; T Saruta; H Suzuki
Journal:  Clin Nephrol       Date:  2000-11       Impact factor: 0.975

5.  Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.

Authors:  C W McIntyre; R J Fluck; S H Lambie
Journal:  Clin Nephrol       Date:  2001-09       Impact factor: 0.975

6.  On the specificity of assays to detect circulating immunoglobulin A-fibronectin complexes: implications for the study of serologic phenomena in patients with immunoglobulin A nephropathy.

Authors:  F Eitner; M Schulze; R Brunkhorst; K M Koch; J Floege
Journal:  J Am Soc Nephrol       Date:  1994-12       Impact factor: 10.121

7.  Renal injury from angiotensin II-mediated hypertension.

Authors:  R J Johnson; C E Alpers; A Yoshimura; D Lombardi; P Pritzl; J Floege; S M Schwartz
Journal:  Hypertension       Date:  1992-05       Impact factor: 10.190

8.  IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est.

Authors:  L Frimat; S Briançon; D Hestin; B Aymard; E Renoult; T C Huu; M Kessler
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

9.  Treatment of vasculitic IgA nephropathy.

Authors:  L Harper; M A Ferreira; A J Howie; C O Savage; N T Richards; J Michael; D Adu
Journal:  J Nephrol       Date:  2000 Sep-Oct       Impact factor: 3.902

10.  Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis.

Authors:  Wilhelm Kriz; Bruni Hähnel; Hiltraud Hosser; Tammo Ostendorf; Soeren Gaertner; Bettina Kränzlin; Norbert Gretz; Fujio Shimizu; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.